Clinical Empowerment, Leading the Future: Bioyitech Launches Top-Tier Clinical Probiotics for Novel Nutrition
The two-day 2025 Novel Nutrition Conference recently concluded successfully in Guangzhou. At this conference, Bioyitech made a significant debut with its exclusive product, Bioyitech's strains (Booth No.: A09). During the event, they officially released the positive results from their randomized, double-blind clinical study conducted at the Second People's Hospital of Guangdong Province (a Grade III Class A hospital) for patients with hyperuricemia. This marks a key advancement in the field of precision probiotic intervention for uric acid metabolism, drawing considerable attention both within and outside the venue.
Throughout the exhibition, the Bioyitech A09 booth was bustling with activity, attracting numerous industry experts, brand representatives, nutritionists, and media for discussions. The centerpiece of the exhibition – a uric acid intervention strategy validated by randomized, double-blind clinical trials" – served as the cornerstone of trust in all communications with visitors.
Many professional visitors expressed that in the current era of severe homogenization in the probiotic market, witnessing products with rigorous clinical evidence and clearly defined targeted applications has undoubtedly injected new vitality and confidence into the market. The technical team at our booth engaged in in-depth and enthusiastic discussions with visitors regarding strain specificity, clinical design details, and mechanisms of action.
Awarded a Prestigious Honor: Bioyitech Wins Microbial Ecology Technology Pioneer Award
Bioyitech's Probiotics powder, recognized for its dual innovation in strain research and development and clinical validation, has been honored with the Microbial Ecology Technology Pioneer Award by the conference organizers. This award not only acknowledges the product's excellence but also endorses Bioyitech's philosophy of research-driven market, setting a new benchmark in the field of microbial ecology and health.
Keynote Speech《Clinical Probiotic Intervention for Metabolic Diseases: A Novel Strategy for Functional Foods》
On the morning of November 7th, Dr. Xu Xianrui, Vice President of Research and Development at Bioyitech, delivered a significant keynote speech titled "Clinical Probiotic Intervention for Metabolic Diseases（Uric Acid Reduction&Blood Glucose and Lipid Management）: A Novel Strategy for Functional Foods" in the keynote presentation area. The lecture hall was filled to capacity, with a highly engaged audience.
In his presentation, Dr. Xu systematically detailed the current prevalence of hyperuricemia and unmet market needs. He also presented for the first time to the industry the core data and conclusions from the randomized, double-blind, placebo-controlled clinical trial of Bioyitech's strains for hyperuricemia patients, conducted at the Second People's Hospital of Guangdong Province. He emphasized, "The future of functional foods will inevitably be built upon robust clinical evidence. The success of this clinical study not only validates the efficacy of Bioyitech's strains in a specific application but, more importantly, demonstrates the new potential for probiotics to advance from 'gut health benefits' to 'precision interventions,' offering a replicable new strategy for functional food development."
Looking Ahead: Navigating Towards the New Frontier of Precision Nutrition with Clinical Evidence as Our Guide
Our successful participation in this New Nutrition Conference served not only as a significant brand showcase for Bioyitech but also as a successful initiative to lead industry development trends. Through in-depth discussions with industry peers, we are more convinced than ever: steering with science and navigating with clinical evidence will lead us to the vast blue ocean of precision nutrition, forging a trustworthy new path for national health.
Though the journey is long, the wind is strong; though the task is immense, we embark anew. Bioyitech will leverage this conference as a new starting point to deepen scientific research and innovation, dedicating ourselves to bringing more clinically validated precision nutrition solutions to market. Together with partners from all sectors, we will jointly forge a healthy future rooted in science and worthy of trust.
